Search - tctmd.com

Displaying 41 - 58 of 58

Sort: Relevancy | Date

News Conference News EuroPCR 2016

Stent ‘Sealing’ of Nonobstructive Saphenous Vein Graft Plaques Fails to Prevent CV Events

Shelley Wood

May 18, 2016

News Daily News

Does the Atherosclerotic Cardiovascular Disease Calculator Overestimate Patient Risk? The Debate Continues

Yael L. Maxwell

May 04, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Michael O'Riordan

March 07, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

Michael O'Riordan

January 28, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Daily News

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

Michael O'Riordan

December 08, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

June 16, 2015

News Daily News

PROSPECT Substudy: Persistently High CRP Predicts Future MACE in ACS Patients After PCI

June 04, 2014

News Daily News

Most Nonculprit Lesions with Plaque Rupture Do not Lead to Increased Events

March 13, 2014

Presentation TCT 2012

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Presenter: Pedro Moreno

October 23, 2012

Advertisement

Stent ‘Sealing’ of Nonobstructive Saphenous Vein Graft Plaques Fails to Prevent CV Events

Does the Atherosclerotic Cardiovascular Disease Calculator Overestimate Patient Risk? The Debate Continues

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

PROSPECT Substudy: Persistently High CRP Predicts Future MACE in ACS Patients After PCI

Most Nonculprit Lesions with Plaque Rupture Do not Lead to Increased Events

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content